NLS Clinical Trials Medtech

Nexstim has presented the final results of a multi-center Phase III trial in stroke rehabilitation (NICHE trial) assessing the company’s Navigated Brain Therapy system (NBT) at the International Stroke Conference in Houston, USA. The presentation, by the trial Principal Investigator, Richard L. Harvey, MD, Rehabilitation Institute of Chicago, summarised the main safety and efficacy results […]

Nexstim announces that, in a recently published clinical article, neurosurgeons report clinical benefits of using Nexstim NBS Brain Mapping technology, for pre-surgical localization of the motor cortex. In a multi-center study at Departments of Neurosurgery at Charite Univärsitetsmedizin, Berlin, Teknische Universität Munchen and University of California San Francisco(1) outcomes of brain surgery performed because of […]

The Finnish company Injeq has initiated clinical trials with its IQ-Needle and its performance has been demonstrated in clinical tests. The IQ-Needle, developed by the Tampere based company Injeq, is equipped with electrodes and a related bio-impedance measuring tissue analyzer for advanced real-time information. It can be applied in several clinical areas, including regional anesthesia, […]

Bonesupport, a company focusing on innovative injectable bioresorbable bone graft substitute products to treat bone voids caused by trauma, infection, disease or related surgery, has announced the publication of a paper in The Bone and Joint Journal. The paper (Single-stage treatment of chronic osteomyelitis with a new absorbable gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite – A prospective series […]

Karolinska Development portfolio company OSSDSIGN presented preliminary data at European Congress of Neurosurgery 2016 in Athens, indicating that OSSDSIGN Cranial may provide better, more permanent solution for cranioplasty, even in a complex patient population. OSSDSIGN found, in a retrospective study of patients undergoing cranioplasty using OSSDSIGN Cranial, 96.7% of patients treated showed no signs of post-operative […]

Norwegian Photocure has announced new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone. The data from the prospective registry, real life, […]